We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.2B
AUM Growth
-$978M
Cap. Flow
-$700M
Cap. Flow %
-13.47%
Top 10 Hldgs %
44.11%
Holding
176
New
13
Increased
49
Reduced
69
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.9M
2
BRKR icon
Bruker
BRKR
+$21.3M
3
AMGN icon
Amgen
AMGN
+$19M
4
EHC icon
Encompass Health
EHC
+$16.6M
5
THC icon
Tenet Healthcare
THC
+$15.6M

Top Sells

Rank Stock Value
1
OPCH icon
Option Care Health
OPCH
+$51.8M
2
EPIX
ESSA Pharma
EPIX
+$47.8M
3
EXAS
Exact Sciences
EXAS
+$47M
4
CDNA icon
CareDx
CDNA
+$43.1M
5
EXEL icon
Exelixis
EXEL
+$41.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.04%
3 Communication Services 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
126
Cytokinetics
CYTK
$11B
$515K 0.01%
10,941
– –
BIIB icon
127
Biogen
BIIB
$29.9B
$406K 0.01%
2,652
+18
+0.7% +$3.04K
TVTX icon
128
Travere Therapeutics
TVTX
$5.33B
$402K 0.01%
23,100
-7,900
-25% -$140K
QURE icon
129
uniQure
QURE
$2.68B
$397K 0.01%
+22,500
New +$194K
ASND icon
130
Ascendis Pharma A/S
ASND
$16.7B
$344K 0.01%
+2,500
New +$329K
ZLAB icon
131
Zai Lab
ZLAB
$2.17B
$340K 0.01%
+13,000
New +$361K
MDGL icon
132
Madrigal Pharmaceuticals
MDGL
$12.6B
$339K 0.01%
1,100
– –
MRUS
133
DELISTED
Merus
MRUS
$336K 0.01%
8,000
– –
XENE icon
134
Xenon Pharmaceuticals
XENE
$6.32B
$321K 0.01%
8,200
– –
DNLI icon
135
Denali Therapeutics
DNLI
$3.67B
$320K 0.01%
15,700
– –
ADMA icon
136
ADMA Biologics
ADMA
$1.92B
$290K 0.01%
16,900
-9,000
-35% -$169K
BBIO icon
137
BridgeBio Pharma
BBIO
$16.5B
$285K 0.01%
10,400
– –
ROIV icon
138
Roivant Sciences
ROIV
$25.2B
$284K 0.01%
+24,000
New +$284K
BPMC
139
DELISTED
Blueprint Medicines
BPMC
$279K 0.01%
3,200
– –
MLTX icon
140
MoonLake Immunotherapeutics
MLTX
$1.59B
$238K ﹤0.01%
4,400
– –
ACLX
141
DELISTED
Arcellx
ACLX
$230K ﹤0.01%
3,000
-1,000
-25% -$86.4K
GRMN
142
Garmin
GRMN
$46.9B
$217K ﹤0.01%
1,050
– –
MLYS icon
143
Mineralys Therapeutics
MLYS
$2.35B
$203K ﹤0.01%
16,499
– –
PTCT icon
144
PTC Therapeutics
PTCT
$6.37B
$172K ﹤0.01%
+3,800
New +$163K
OCS icon
145
Oculis Holding
OCS
$672M
$170K ﹤0.01%
+10,000
New +$157K
BIDU icon
146
Baidu
BIDU
$35.8B
$169K ﹤0.01%
2,000
– –
RARE icon
147
Ultragenyx Pharmaceutical
RARE
$2.65B
$168K ﹤0.01%
4,000
– –
KNSA icon
148
Kiniksa Pharmaceuticals
KNSA
$4.83B
$160K ﹤0.01%
+8,100
New +$185K
NRIX icon
149
Nurix Therapeutics
NRIX
$2.43B
$151K ﹤0.01%
8,000
– –
VCYT icon
150
Veracyte
VCYT
$4.52B
$143K ﹤0.01%
3,600
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2024 Portfolio in Review

As of Q4 2024, Bellevue Group held 176 positions worth $5.2B, down 16% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Bellevue Group withdrew a net $700M in Q4 2024, closing 15 positions and reducing 69 holdings. Its most notable exit was Option Care Health, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Bruker worth $21.1M.

  • Bellevue Group's largest Q4 2024 buy was Bruker: 359,588 shares worth $21.1M.
  • Bellevue Group added most to Merck in Q4 2024, an estimated $22.9M increase.
  • Bellevue Group's biggest Q4 2024 reduction was Exact Sciences, cutting an estimated $47M.
  • Bellevue Group fully exited Option Care Health in Q4 2024, selling an estimated $51.8M.
  • Bellevue Group's ten largest holdings make up 44% of its $5.2B portfolio in Q4 2024.
  • Bellevue Group opened 13 new positions and closed 15 in Q4 2024.
  • Bellevue Group's portfolio value fell 16% quarter-over-quarter to $5.2B.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.